Disease Landscape and Forecast Insights

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment based largely on…

Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness if left untreated. DME…

Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of TNF-alpha inhibitors and the IL-12/23 inhibitor ustekinumab (Johnson &…

Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula. We expect the historical mainstays of…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 726 currently available and novel biosimilar products, detailing…

The PsA therapy market has become highly dynamic with the recent launches of targeted agents such as AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Upcoming launches in the next few years will…

Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab ± ipilimumab, and nivolumab plus relatlimab) and BRAF/MEK inhibitor combinations (e.g., vemurafenib plus cobimetinib) have greatly…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…